Intervention Review

You have free access to this content

Ivermectin for onchocercal eye disease (river blindness)

  1. Henry OD Ejere1,*,
  2. Ellen Schwartz2,
  3. Richard Wormald3,
  4. Jennifer R Evans3

Editorial Group: Cochrane Eyes and Vision Group

Published Online: 15 AUG 2012

Assessed as up-to-date: 2 APR 2012

DOI: 10.1002/14651858.CD002219.pub2


How to Cite

Ejere HOD, Schwartz E, Wormald R, Evans JR. Ivermectin for onchocercal eye disease (river blindness). Cochrane Database of Systematic Reviews 2012, Issue 8. Art. No.: CD002219. DOI: 10.1002/14651858.CD002219.pub2.

Author Information

  1. 1

    Hode Internal Medicine, Texas, USA

  2. 2

    Institute of Ophthalmology, London, UK

  3. 3

    London School of Hygiene & Tropical Medicine, Cochrane Eyes and Vision Group, ICEH, London, UK

*Henry OD Ejere, Hode Internal Medicine, 125 South Park Drive, Suite F, Brownwood, Texas, 76801, USA. hodejere2000@yahoo.com.

Publication History

  1. Publication Status: Stable (no update expected for reasons given in 'What's new')
  2. Published Online: 15 AUG 2012

SEARCH

References

References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
Abiose 1993 {published data only}
  • Abiose A, Jones BR, Cousens SN, Murdoch I, Cassels-Brown A, Babalola OE, et al. Reduction in incidence of optic nerve disease with annual ivermectin to control onchocerciasis. Lancet 1993;341(8838):130-4.
  • Cousens SN, Cassels-Brown A, Murdoch I, Babalola OE, Jatau D, Alexander NDE, et al. Impact of annual dosing with ivermectin on progression of onchocercal visual field loss. Bulletin of the World Health Organization 1997;75(3):229-36.
Dadzie 1989 {published data only}
  • Dadzie KY, Awadzi K, Bird AC, Schulz-Key H. Ophthalmological results from a placebo controlled comparative 3-dose ivermectin study in the treatment of onchocerciasis. Tropical Medicine and Parasitology 1989;40(3):355-60.
Taylor 1988 {published data only}
  • Newland HS, White AT, Greene BM, D'Anna SA, Keyvan-Larijani E, Aziz MA, et al. Effect of single-dose ivermectin therapy on human onchocerca volvulus infection with onchocercal ocular involvement. British Journal of Ophthalmology 1988;72(8):561-9.
  • Taylor HR, Semba RD, Newland HS, Keyvan-Larijani E, White A, Dukuly Z, et al. Ivermectin treatment of patients with severe ocular onchocerciasis. American Journal of Tropical Medicine and Hygiene 1989;40(5):494-500.
  • White A, Newland HS, Taylor HR, Semba RD, Erttmann KD, Keyvan-Larijani E, et al. Controlled trial and dose-finding study of ivermectin for treatment of onchocerciasis. Journal of Infectious Diseases 1987;156(3):463-70.
Whitworth 1991a {published data only}
  • Whitworth JAG, Gilbert CE, Mabey DM, Maude GH, Morgan D, Taylor DW. Effects of repeated doses of ivermectin on ocular onchocerciasis: community-based trial in Sierra Leone. Lancet 1991;338(8775):1100-3.
  • Whitworth JAG, Morgan D, Maude GH, Downham MD, Taylor DW. A community trial of ivermectin for onchocerciasis in Sierra Leone: adverse reactions after the first five treatment rounds. Transactions of the Royal Society of Tropical Medicine and Hygiene 1991;85(4):501-5.
  • Whitworth JAG, Morgan D, Maude GH, Luty AJF, Taylor DW. A community trial of ivermectin for onchocerciasis in Sierra Leone: clinical and parasitological responses to four doses given at six-monthly intervals. Transactions of the Royal Society of Tropical Medicine and Hygiene 1992;86(3):277-80.
  • Whitworth JAG, Morgan D, Maude GH, Taylor DW. Community-based treatment with ivermectin. Lancet 1988;ii:97-8.

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
Gardon 2002 {published data only}
  • Fobi G, Gardon J, Kamgno J, Aimard-Favennec L, Lafleur C, Gardon-Wendel N, et al. A randomized, double-blind, controlled trial of the effects of ivermectin at normal and high doses, given annually or three-monthly, against Onchocerca volvulus: ophthalmological results. Transactions of the Royal Society of Tropical Medicine and Hygiene 2005;99(4):279-89.
  • Gardon J, Boussinesq M, Kamgno J, Gardon-Wendel N, Demanga-Ngangue, Duke BOL. Effects of standard and high doses of ivermectin on adult worms of Onchocerca volvulus: a randomised controlled trial. Lancet 2002;360(9328):203-10.

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
Abiose 1994
  • Abiose A, Murdoch I, Babalola OE, Cousens S, Liman I, Onyema J, et al. The distribution and aetiology of blindness and visual impairment in mesoendemic onchocercal communities in Kaduna State, Nigeria. British Journal of Ophthalmology 1994;78(1):8-13.
Abiose 1998
  • Abiose A. Onchocercal eye disease and the impact of Mectizan treatment. Annals of Tropical Medicine and Parasitology 1998;92(Suppl 1):S11-22.
Abiose 2000
Akogun 2000
Aziz 1982
Bird 1980
  • Bird AC, el Sheikh H, Anderson J, Fuglsang H. Changes in visual function and in the posterior segment of the eye during treatment of onchocerciasis with diethylcarbamazine citrate. British Journal of Ophthalmology 1980;64(3):191-200.
Boussinesq 1998
  • Boussinesq M, Gardon J, Gardon-Wendel N, Kamgno J, Ngoumou P, Chippaux JP. Three probable cases of Loa loa encephalopathy following ivermectin treatment for onchocerciasis. American Journal of Tropical Medicine and Hygiene 1998;58(4):461-9.
Burnham 1998
Chijioke 1992
Chippaux 1999
  • Chippaux J, Boussinesq M, Fobi G, Lafieur C, Auduge A, Banos MJ, et al. Effect of repeated ivermectin treatments on ocular onchocerciasis: evaluation after six to eight dosings. Ophthalmic Epidemiology 1999;6(4):229-46.
Cooper 1996
  • Cooper PJ, Guderian RH, Proano R, Taylor DW. Absence of cellular responses to a putative autoantigen in onchocercal chorioretinopathy. Cellular autoimmunity in onchocercal chorioretinopathy. Investigative and Ophthalmological Visual Science 1996;37(9):1717-9.
Cooper 1997
De-Sole 1989
  • De-Sole G, Remme J, Awadzi K, Accorsi S, Alley ES, Ba O, et al. Adverse reactions after large-scale treatment of onchocerciasis with ivermectin: combined results from eight community trials. Bulletin of the World Health Organization 1989;67(6):707-19.
Diawara 2009
  • Diawara L, Traore MO, Badji A, Bissan Y, Doumbia K, Goita SF, et al. Feasibility of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: first evidence from studies in Mali and Senegal. PLoS Neglected Tropical Diseases 2009;3(7):e497.
Gardon 1997
  • Gardon J, Gardon-Wendel N, Demanga N, Kamgno J, Chippaux JP, Boussinesq M. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet 1997;350(9070):2-3.
Glanville 2006
  • Glanville JM, Lefebvre C, Miles JN, Camosso-Stefinovic J. How to identify randomized controlled trials in MEDLINE: ten years on. Journal of the Medical Library Association 2006;94(2):130-6.
Goa 1991
Higgins 2005
  • Higgins JPT, Green S, editors. Assessment of study quality. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]; Section 6. The Cochrane Library, Issue 3, 2005. Chichester, UK: John Wiley & Sons, Ltd.
Higgins 2011
  • Higgins JPT, Altman DG, Sterne, JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated September 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Hise 2007
  • Hise AG, Daehnel K, Gillette-Ferguson I, Cho E, McGarry HF, Taylor MJ, et al. Innate immune responses to endosymbiotic Wolbachia bacteria in Brugia malayi and Onchocerca volvulus are dependent on TLR2, TLR6, MyD88, and Mal, but not TLR4, TRIF, or TRAM. Journal of Immunology 2007;178(2):1068-76.
Hoerauf 2001
  • Hoerauf A, Mand S, Adjei O, Fleischer B, Buttner DW. Depletion of wolbachia endobacteria in Onchocerca volvulus by doxycycline and microfilaridermia after ivermectin treatment. Lancet 2001;357(9266):1415-6.
ISRCTN95189962
  • ISRCTN95189962. Evaluation of the impact of large scale, community directed delivery of doxycycline for the treatment of onchocerciasis: the Anti-Wolbachia (A-WOL) trial. www.controlled-trials.com/ISRCTN95189962/ (accessed 11 May 2012).
Johnson 1998
  • Johnson G, Minassian DC, Weale R (Eds). The Epidemiology of Eye Disease. London: Chapman and Hall, 1998.
Kinnanom 2000
  • Kinnanom KE, Engle RR, Poon BT, Ellis WY, McCall JW, Dzimianski MT. Anticancer agents suppressive for adult parasites of filariasis in Mongolian jirds. Proceedings of the Society for Experimental Biological Medicine 2000;224(1):45-9.
Murdoch 1997
  • Murdoch IE, Jones BR, Cousens S, Liman I, Babalola OE, Dauda J, et al. Visual field constriction as a cause of blindness or visual impairment. Bulletin of the World Health Organization 1997;75(2):141-6.
NCT00790998
  • NCT00790998. Study comparing moxidectin and ivermectin in subjects with Onchocerca Volvulus infection. clinicaltrials.gov/ct2/show/NCT00790998 (accessed 11 May 12).
Pond 1991
  • Pond B. Mass Distribution of Ivermectin: A Handbook for Community Treatment of Onchocerciasis. The International Eye Foundation, 1991.
Remme 1990
  • Remme J, De Sole G, Dadzie KY, Alley ES, Baker RHA, Habbena JDF, et al. Large scale ivermectin distribution and its epidemiological consequences. Acta Leiden 1990;59(1-2):177-91.
Review Manager 2011 [Computer program]
  • The Cochrane Collaboration, The Nordic Cochrane Centre. Review Manager (RevMan). Version 5.1. Copenhagen: The Cochrane Collaboration, The Nordic Cochrane Centre, 2011.
Richards 2000
Rolland 1974
  • Rolland A. Results of 2 eye examinations carried out with an interval of 6 years in 2 Upper Volta villages where onchocerciasis is endemic. Bulletin of the World Health Organization 1974;51(3):257-61.
Saint Andre 2002
Stevenson 1999
Taylor 1990
Taylor 2000
  • Taylor M. Filarial nematodes: a bug's life?. Filarial Update 2000;2(1):10-1.
Tekle 2012
  • Tekle AH, Elhassan E, Isiyaku S, Amazigo UV, Bush S, Noma M, et al. Impact of long-term treatment of onchocerciasis with ivermectin in Kaduna State, Nigeria: first evidence of the potential for elimination in the operational area of the African Programme for Onchocerciasis Control. Parasites and Vectors 2012;5:28.
Trpis 1990
  • Trpis M, Childs JE, Fryauff DJ, Greene BM, Williams PN, Munoz BE, et al. Effect of mass treatment of of a human population with ivermectin on transmission of Onchocerca volvulus by Simulium yahense in Liberia, West Africa. American Journal of Tropical Medicine and Hygiene 1990;42(2):148-56.
White 1987
  • White A, Newland HS, Taylor HR, Semba RD, Erttmann KD, Keyvan-Larijani E, et al. Controlled trial and dose-finding study of ivermectin for treatment of onchocerciasis. Journal of Infectious Diseases 1987;156(3):463-70.
White 2008
Whitworth 1991b
  • Whitworth JA, Morgan D, Maude GH, McNicholas AM, Taylor DW. A field study of the effect of ivermectin on intestinal helminths in man. Transactions of the Royal Society of Tropical Medicine and Hygiene 1991;85(2):232-4.
Whitworth 1992
WHO 1985
  • World Health Organization. Ten years of onchocerciasis control in West Africa. OCP/GVA/85.1B 1985.
WHO 2000
  • World Health Organization. Onchocerciasis (River blindness). Fact sheet No 95 Revised 2000.
Winthrop 2011
  • Winthrop KL, Furtado JM, Silva JC, Resnikoff S, Lansingh VC. River blindness: an old disease on the brink of elimination and control. Journal of Global Infectious Diseases 2011;3(2):151-5.

References to other published versions of this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
  4. References to other published versions of this review
Ejere 2001
Ejere 2009
  • Ejere HOD, Schwartz E, Wormald R, Evans JR. Ivermectin for onchocercal eye disease (river blindness). Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD002219]